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Opioid receptor signaling, analgesic 
and side effects induced by a 
computationally designed  
pH-dependent agonist
Viola Spahn  1, Giovanna Del Vecchio  1, Antonio Rodriguez-Gaztelumendi1,4, Julia Temp  1, 
Dominika Labuz1, Michael Kloner1, Marco Reidelbach2, Halina Machelska1, Marcus Weber3 & 
Christoph Stein  1
Novel pain killers without adverse effects are urgently needed. Opioids induce central and intestinal 
side effects such as respiratory depression, sedation, addiction, and constipation. We have recently 
shown that a newly designed agonist with a reduced acid dissociation constant (pKa) abolished pain by 
selectively activating peripheral μ-opioid receptors (MOR) in inflamed (acidic) tissues without eliciting 
side effects. Here, we extended this concept in that pKa reduction to 7.22 was achieved by placing a 
fluorine atom at the ethylidene bridge in the parental molecule fentanyl. The new compound (FF3) 
showed pH-sensitive MOR affinity, [35S]-GTPγS binding, and G protein dissociation by fluorescence 
resonance energy transfer. It produced injury-restricted analgesia in rat models of inflammatory, 
postoperative, abdominal, and neuropathic pain. At high dosages, FF3 induced sedation, motor 
disturbance, reward, constipation, and respiratory depression. These results support our hypothesis 
that a ligand’s pKa should be close to the pH of injured tissue to obtain analgesia without side effects.
Opioid receptor agonists are the most powerful drugs to treat severe acute and cancer-related pain. However, 
major problems have emerged due to their epidemic misuse and adverse effects1. These side effects comprise seda-
tion, respiratory depression, addiction, nausea, and constipation, and are mediated by central or intestinal opioid 
receptors2,3. The analgesic effects result from the activation of both central and peripheral opioid receptors via 
inhibitory G-proteins, which dissociate into Gαi and Gβγ subunits. Further downstream signaling leads to sup-
pression of adenylyl cyclases and the modulation of ion channels, resulting in an overall decrease in neuronal 
excitability2. Many experimental and clinical studies revealed that a substantial proportion of opioid analge-
sia is mediated by the activation of opioid receptors on peripheral sensory neurons (reviewed in3,4). Numerous 
pain syndromes (e.g. arthritis, neuropathy, postoperative pain, cancer) are accompanied by injury-induced 
tissue acidosis and upregulation of such peripheral opioid receptors3,5–7. Therefore, the potential of peripheral 
opioid receptors as drug targets is increasingly recognized8,9. In contrast to previous pharmacokinetic concepts 
(reviewed in3), we recently developed a new pharmacodynamics-based design for peripherally-acting opioids 
lacking central or intestinal side effects5. This strategy is based on computational simulations of pathological 
receptor conformations and the finding that the protonation state of a ligand is crucial for its activity at opioid 
receptors. We hypothesized that the ligand’s pKa should be reduced to values close to the acidic pH of injured 
tissue. This was achieved by fluorination of the piperidine ring in the μ-opioid receptor (MOR) agonist fenta-
nyl, leading to the compound (±)-N-(3-fluoro-1-phenethylpiperidine-4-yl)-N-phenyl propionamide (NFEPP). 
In addition, our original computer simulations suggested hydrogen/fluorine exchange in fentanyl′s ethylidene 
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bridge5. Accordingly, the compound (±)-N-[1-(2-fluoro-2-phenylethyl)piperidine-4-yl]-N-phenyl propionamide 
(FF3) was synthesized by a contractor (ASCA GmbH Berlin) and tested in vitro and in vivo in the present study.
Results
Computational design of FF3. Our previous in silico studies demonstrated that exchanging hydrogen by 
fluorine at distinct positions in the fentanyl molecule decreases its pKa value5. An electron withdrawing moiety 
within a distance of two carbon bonds (Fig. 1A, green circles) of the acidic nitrogen atom (Fig. 1A, blue circle) 
is able to decrease the pKa such that the new molecule (FF3) is protonated in acidic and deprotonated in healthy 
tissue5. By choosing the fluorine atom, one hydrogen is replaced by only one other atom. Therefore, the overall 
size, geometry, and MOR binding properties of FF3 should not change significantly. To estimate its pKa, we used 
the B3LYP functional with a 6–31 + G* basis. In contrast to single starting structures used previously5, ensembles 
of structures derived from molecular dynamics simulations were now the basis for the calculations yielding an 
averaged pKa value of 6.01. Experimental measurements by a contractor resulted in a pKa of 7.22 (Table 1).
FF3 preferentially binds to and activates MOR at low pH. In membrane preparations of 
MOR-transfected Human Embryonic Kidney-293 (HEK293) cells, FF3 showed increased potency to displace the 
radioactively-labeled standard MOR ligand [3H]-[D-Ala2, N-MePhe4, Gly-ol]-enkephalin (DAMGO) (4 nM), as 
demonstrated by the significantly reduced IC50 at pH 6.5 compared to physiological pH 7.4 (Fig. 1B,C). In the 
[35S]-GTPγS binding assay, the EC50 of FF3 was significantly lower at pH 6.5 than at pH 7.4 (Fig. 1E). In con-
trast, we found no pH-dependent differences in fentanyl-induced G-protein activation in this assay (Fig. 1D). 
Using real-time fluorescence resonance energy transfer (FRET) in HEK293 cells transfected with MOR, Gβ1, 
Gαi1-mTqΔ6, and cpVenus-Gγ2, we observed dose-dependent dissociation of G-protein subunits (ΔFRET 
between Gαi1-mTqΔ6 and cpVenus-Gγ2) upon treatment with fentanyl at both pH 7.4 and 6.5, while FF3 induced 
dose-dependent effects only at pH 6.5 but not at pH 7.4 (no fitting was found, Fig. 1F). At pH 6.5 (Fig. 1G), time 
courses of FRET responses to both fentanyl and FF3 (100 μM) differed significantly from those of vehicle-treated 
cells, whereas at pH 7.4 only fentanyl induced significant effects compared to vehicle (Fig. 1H).
FF3 produces analgesia selectively in injured tissue. To assess analgesic efficacy in vivo, we used four 
clinically relevant rat models of pain, unilateral complete Freund’s adjuvant (CFA)-induced inflammation or 
plantar incision of the hindpaw, intraperitoneal (i.p.) injection of acetic acid, and unilateral chronic constriction 
injury (CCI) of the sciatic nerve. Four days following CFA injection (Fig. 2), 2 h after incision (Fig. 3), and 14 days 
following CCI (Fig. 4), rats developed mechanical hyperalgesia indicated by reduced paw pressure thresholds 
(PPT), mechanical allodynia manifested by decreased paw withdrawal thresholds (PWT) to von Frey filaments, 
and heat hyperalgesia indicated by lowered paw withdrawal latencies (PWL) in ipsilateral compared to contralat-
eral paws, and to thresholds before injury.
Intravenous FF3 (4–16 μg/kg, i.v.) produced dose-dependent analgesia manifested by increased PPT, PWT, 
and PWL between 15–45 min after injection. These effects occurred exclusively ipsilateral to the injuries, without 
affecting contralateral paws. The most effective doses of FF3 (16 and 12 μg/kg, i.v.) reversed PPT, PWT, and PWL 
in ipsilateral paws to values before CFA injection (Fig. 2), incision (Fig. 3), or CCI (Fig. 4). Abdominal constric-
tions (writhings), evaluated over 30 min after i.p. acetic acid (1%), were dose-dependently attenuated by FF3 
(4–16 µg/kg, i.v.) injected 5 min after acetic acid (see Supplementary Fig. S1).
To examine the contribution of peripheral opioid receptors, we used naloxone methiodide (NLXM), an opioid 
receptor antagonist that does not cross the blood-brain barrier10, in the CCI model. The analgesic effects pro-
duced by FF3 (12 μg/kg, i.v.) in ipsilateral limbs were abolished by NLXM (50 µg) injected at the nerve injury site 
(Fig. 4D), indicating that FF3-induced analgesia is mediated by local opioid receptors. No changes were observed 
in contralateral paws (Fig. 4D).
FF3 induces central and intestinal side effects at high doses. Next, we examined typical opioid side 
effects mediated centrally or intestinally (sedation, motor impairment, reward, respiratory depression, consti-
pation). Analogous to our previous study5, we tested FF3 (30–150 µg/kg) in comparison to the standard opioids 
fentanyl (30 µg/kg) and morphine (1–64 mg/kg) following subcutaneous (s.c.) injection.
Locomotor activity, measured as the distance traveled within 30 min after drug injections, was decreased by 
fentanyl (30 µg/kg), and by the highest doses of morphine (16 mg/kg) and FF3 (150 µg/kg) (Fig. 5A). At 5 min 
after administration of any compound, locomotor activity was significantly lower compared to vehicle (see 
Supplementary Fig. S2). Impaired motor coordination, measured by an accelerating Rota-Rod, was produced by 
fentanyl (30 µg/kg), by all doses of morphine (2–16 mg/kg), and by the two highest doses of FF3 (60–150 µg/kg) 
(Fig. 5B). Constipation, assessed as reduced defecation, was evoked by fentanyl (30 µg/kg), by all doses of mor-
phine (1–16 mg/kg), and by the highest dose of FF3 (150 µg/kg) (Fig. 5C). In the unbiased conditioned place 
preference test, fentanyl (30 µg/kg), morphine at most doses (2–16 mg/kg), and FF3 at all doses (30–150 µg/kg) 
produced preference for the drug-associated compartment (Fig. 5D). Heart rate (Fig. 6A) and oxygen saturation 
(Fig. 6B) were transiently (5–15 min) reduced by FF3 at the highest dose (150 µg/kg), whereas morphine impaired 
these parameters at all doses (8–64 mg/kg) over the entire period (60 min). Respiratory rate was unaffected by FF3 
(30–150 µg/kg), and transiently elevated by morphine (16–32 mg/kg) (Fig. 6C).
Discussion
We now expanded our concept to develop pain killers that selectively target opioid receptors in peripheral 
damaged tissues. We have refined the computational simulations to study injury-specific opioid agonists based 
on decreased pKa values and altered ligand-receptor interactions. Binding and activation of MOR by the new 
compound FF3 was enhanced at acidic pH. In models mimicking inflammatory, postoperative, neuropathic, 
and abdominal pain, FF3 dose-dependently reduced nociception exclusively in the injured tissues. Importantly, 
www.nature.com/scientificreports/
3SCIenTIFIC REPORTS |  (2018) 8:8965  | DOI:10.1038/s41598-018-27313-4
Figure 1. FF3 preferentially binds to and activates MOR at low pH in HEK293 cells. (A) Chemical structures 
of fentanyl (Fen) (left) and (±)-N-[1-(2-fluoro-2-phenylethyl)piperidine-4-yl]-N-phenyl propionamide (FF3) 
(right). The blue circle highlights the acidic nitrogen atom subjected to pH-dependent protonation in whose 
vicinity electrons may be withdrawn to reduce the pKa value. Green circles denote CH2-groups where a single 
hydrogen may be replaced by a fluorine. (B) Displacement of bound [³H]-DAMGO by FF3 at pH 6.5 and 7.4. 
(C) IC50 calculated from B) at pH 6.5 and 7.4 (***P < 0.001, unpaired t-test, n = 6). (D,E) EC50 of fentanyl- (D) 
and FF3- (E) induced [35S]-GTPγS-binding at pH 6.5 and 7.4 (**P < 0.01, unpaired t-test, n = 5–6). (F) Gαi-
mediated FRET responses (ΔFRET between Gαi-mTqΔ6 and cpVenus-Gγ2) to fentanyl and FF3. FF3 at pH 
7.4 did not induce significant ΔFRET % compared to vehicle. Curves are derived by nonlinear regression fits 
constrained to each maximum effect. (G) Time course of FRET responses to fentanyl and FF3 (100 μM) at pH 
6.5 differ from those of vehicle-treated cells (*P < 0.05, **P < 0.01 vs. vehicle-treated cells at the corresponding 
pH, one-way RM-ANOVA and Dunnett’s test, n = 10). (H) At pH 7.4, only fentanyl (100 µM) induced 
significant FRET responses compared to vehicle (*P < 0.05 vs. vehicle-treated cells at the corresponding pH, 
one-way RM-ANOVA and Dunnett’s test, n = 10). Data are means ± SEM.
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injury-induced tissue acidosis was measured in inflammatory and postoperative pain models5. However, high 
doses of FF3 induced sedation, motor impairment, reward, constipation, and respiratory depression.
In contrast to other strategies to achieve analgesia without side effects such as ion channel antagonists, biva-
lent opioid receptor ligands, biased ligands, abuse deterrent opioids (reviewed in9), the activation of peripheral 
opioid receptors selectively eliminates the source of pain generation in injured tissues. To this end, we pursued 
a novel pharmacodynamics-based approach analyzing interactions between opioid receptors and ligands in 
injury-induced tissue inflammation and acidosis. These studies underlined the importance of protonation for 
receptor binding and activation. In contrast to commonly used opioid drugs (Table 2), our previously designed 
ligand NFEPP with a pKa value reduced to 6.8 displayed enhanced binding and activation of MOR in vitro, and 
analgesic activity selectively in injured tissue without side effects in vivo5.
Additional quantum chemical calculations suggested replacement of hydrogens at an alternative position in 
the fentanyl molecule, as denoted by the derivatives 12 and 13 in Fig. 1A of our previous publication5. Among 
possible electronegative moieties reducing pKa values (in decreasing order of the relative inductive effect: NH3(+) 
> NO2 > CN > SO3H > CHO > CO > COOH > COCl > CONH2 > F > Cl > Br > I > OH > NH2 > C6H5 > H), 
the fluorine atom is the most suitable because one hydrogen is replaced by only one other atom, thus avoiding 
significant changes in the overall size or geometry of the molecule. According to our original simulations, the 
racemic molecule FF3 had an estimated mean pKa value of 5.21 and more negative binding energies (Gibbs free 
energy, ΔG) under injured/acidic conditions (mean ΔG of H-F12 and H-F13 = −13.45) compared to nonin-
jured/neutral conditions (mean ΔG of H-F12 and H-F13 = −9,25)5. Here, we refined our pKa estimation by 
another method11,12. The previous calculations were based on only one three-dimensional structure of each deriv-
ative5. This is suboptimal, since these molecules are flexible in reality. We now used the structural formula of 
the molecule as a starting point, and averaged the pKa estimation/calculation for a canonical ensemble of dif-
ferent structures13. The recalculated pKa of FF3 (6.01) is now closer to the experimentally obtained value (7.22). 
However, there are still differences between calculated (both methods) and experimentally determined pKa val-
ues, which are most likely due to the difficulty to determine solvation energies by computational methods14. 
Although generally recommended12, neither of these calculations used experimentally obtained pKa values of 
related molecules because such measurements were not available so far. Previous publications on computational 
methods for pKa estimation suggest that approaches based on first principles (as in the present study) are pref-
erable to empirical models based on statistics15. Therefore, a combination of our method with experimentally 
obtained pKa values of related molecules appears most promising for the future.
Some results obtained with FF3 were similar to NFEPP5: FF3-induced MOR binding and G-protein dissocia-
tion dropped at physiological pH compared to acidic conditions (Table 1). Mechanical and thermal hyperalgesia 
as well as mechanical allodynia were reduced exclusively in injured limbs without effects in the contralateral 
uninjured limbs. Additionally, FF3 produced dose-dependent analgesia in the abdominal writhing assay. NLXM 
reversed the analgesic effect of FF3 in the CCI model, supporting the selective activation of peripheral opioid 
receptors. In contrast to NFEPP, FF3 produced side effects at higher dosages than those eliciting analgesia. In par-
ticular, our finding that FF3 induced conditioned place preference indicates its abuse liability. It is most likely that 
a pKa value of 7.22 is not low enough to restrict FF3′s activity to injured/acidic tissue, although analgesic doses 
Molecule FF3 Fentanyl NFEPP
Structure
Replaced hydrogen 
(indexed above and in5) 12 13 — 3 7
Calculated pKa
6.31 ± 1.18 5.71 ± 0.89
9.11 ± 0.14
6.73 6.93
Mean = 6.01 Mean = 6.83
Function for pKa 
calculation B3LYP/6-31 + G*//B3LYP/6-31 + G*
B3LYP/6-31 + G*//HF/6-31 + G* 
published in5
Experimentally 
obtained pKa at 25 °C
7.22 ± 0.01+ 8.43 ± 0.0532,33 6.82 ± 0.065
IC50 (nM) (Binding)
pH 6.5 7.1 ± 1.4 6.9 ± 1.1# 18.3 ± 3.3#
pH 7.4 48.3 ± 6.4 4.8 ± 0.7# 81.9 ± 22.1#
EC50 (nM) (GTPγS)
pH 6.5 47.2 ± 24.2 125.5 ± 20.6 Not determined
pH 7.4 231.4 ± 47.9 96.1 ± 16.6 Not determined
EC50 (nM) (FRET)
pH 6.5 33.92 8.31 Not determined
pH 7.4 Not obtainable 4.74 Not determined
Table 1. pKa, IC50 and EC50 values of FF3, fentanyl and NFEPP. +This pKa value was experimentally measured by 
a contractor (Sirius Analytical, UK). #These IC50 values were the basis for the Ki value calculation published in5.
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did not affect contralateral/healthy limbs in the nociceptive tests. This supports our hypothesis that the pKa of a 
ligand should be close to the pH of injured tissue (as shown for NFEPP, see Table 1) to obtain selective peripheral 
analgesia without side effects. In addition, possible changes of receptor conformation due to acidosis-induced 
altered protonation states of amino acid residues must be taken into account in the design of ligands. Thus, fur-
ther refinement of the computational calculations is necessary to enable reliable pKa predictions leading to novel 
structures of peripherally selective agonists.
Methods
Quantum chemical pKa calculations. The pKa-values were estimated using Gaussian 0916 and the quan-
tum-chemical method published previously13. To predict Gibbs free energy changes correlated with deprotona-
tion in water, the geometries of fentanyl and FF3, in gas-phase and in solution, were fully optimized employing 
density functional theory using B3LYP with the 6–31 + G* basis set (Becke’s three-parameter hybrid exchange 
functional and Lee-Yang-Parr correlation functional). In solvation calculations, the integral equation formula-
tion of the polarizable continuum model (IEF-PCM) was applied. Thermal corrections to the Gibbs free energy 
at 298.15 K were determined at the same level. To consider the dependency of the pKa-value on the molecular 
conformation13, pKa calculations for either molecular species were performed from 10 different starting confor-
mations, generated by 10 ns gas-phase molecular dynamics simulations at 298.15 K using GROMACS 2016.117.
Figure 2. Systemic FF3 dose-dependently reduces pain selectively in inflamed tissue in the CFA model. Effects 
after intravenous (i.v.) injection of FF3 in rats with unilateral hindpaw inflammation on mechanical (PPT (A) and 
PWT (B)) and heat (PWL (C)) thresholds in inflamed (left panels) and noninflamed (right panels) hindpaws were 
measured before (0) and 15–60 min after injection, on day 4 after CFA (*P < 0.05, **P < 0.01, ***P < 0.001 vs. 
vehicle, two-way RM-ANOVA and Bonferroni’s multiple comparison test, n = 9, means ± SEM).
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Chemicals/Drugs. Fentanyl citrate, naloxone hydrochloride (NLX), NLXM, Guanosine 5′- [γ-thio]triphos-
phate tetralithium salt (cold GTPγS) and Guanosine 5′-diphosphate sodium salt (GDP) were purchased from 
Sigma-Aldrich (Taufkirchen, Germany). [3H]-DAMGO and [35S]-GTPγS were purchased from Perkin Elmer 
(Rodgau-Jügesheim, Germany).
FF3 was synthesized according to our design by a contractor (ASCA GmbH, Berlin, Germany) leading to the 
racemate FF3 (Fig. 1B). The experimental measurement of the pKa value was performed by a contractor (Sirius 
Analytical Ltd., Forest Row, UK). For in vitro experiments, fentanyl and FF3 were initially dissolved in water or 
dimethyl-sulfoxide (DMSO) and diluted in assay buffer to final concentrations. For in vivo experiments, FF3 was 
dissolved in DMSO and diluted with 0.9% NaCl to obtain the final concentrations. The maximum DMSO concen-
tration was 4.2% for s.c., and 0.5% for i.v. injections. Fentanyl and NLXM were dissolved in 0.9% NaCl. Control 
groups were treated with DMSO or NaCl, respectively.
Cell cultures. Wild type and MOR-expressing HEK293 cells were maintained in DMEM media 
(Sigma-Aldrich, Taufkirchen, Germany) supplemented with 10% fetal bovine serum and 1% penicillin/streptomy-
cin in the absence or presence of 0.1 mg/ml geneticin (Biochrom AG, Berlin, Germany), respectively, in 5% CO2 
at 37 °C. According to their confluence, cells were passaged 1:3–1:10 every second to third day from P8 to P2818.
Figure 3. Systemic FF3 dose-dependently reduces incisional pain selectively in injured tissue. Effects after 
intravenous (i.v.) injection of FF3 in rats with unilateral hindpaw incision. The effects on mechanical (PPT (A) 
and PWT (B)) and heat (PWL (C)) thresholds in injured (left panels) and noninjured (right panels) hindpaws 
before (0) and 15–60 min after injection, at 2 h following paw incision (*P < 0.05; **P < 0.01; ***P < 0.001 vs. 
vehicle, two-way RM-ANOVA and Bonferroni’s multiple comparison test, n = 9, means ± SEM.
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Radioligand binding assays. HEK293 cells stably expressing rat MOR were cultured in flasks with a 
growth area of 175 cm². Cells were washed twice with ice-cold assay buffer (Trizma® Preset Crystals, 50 mM, pH 
7.4) (Sigma-Aldrich), then scratched from the culture flask in 10 ml ice cold assay buffer, homogenized and cen-
trifuged twice at 42,000 g for 20 min at 4 °C as described previously7,19,20. Protein concentration was determined 
Figure 4. Systemic FF3 dose-dependently reduces CCI-induced pain via peripheral opioid receptors. Effects 
after intravenous (i.v.) injection of FF3 in rats with CCI on mechanical (PPT (A) and PWT (B)) and heat (PWL 
(C)) thresholds in injured (left panels) and noninjured (right panels) hindlimbs before (0) and 15–60 min after 
injection, at 14 days following CCI (*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, two-way RM-ANOVA and 
Bonferroni’s multiple comparison test, n = 9, means ± SEM). (D) Contribution of peripheral opioid receptors to 
the effects of FF3. NLXM (50 μg) was injected at the site of nerve injury before FF3 (12 μg/kg, i.v.). Effects on PPT 
were measured 15 min after injection in injured (left panels) and noninjured (right panels) hindlimbs (**P < 0.01 
vs. FF3+ vehicle at 15 min, t-test; #P < 0.05, ###P < 0.001 vs. baseline, paired t-test, n = 9, means ± SEM).
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according to the Bradford method21. The half maximal inhibitory concentration (IC50) of FF3 required to displace 
4 nM of the standard MOR ligand [3H]-DAMGO from the receptor was determined at pH values 6.5 and 7.4. A 
protein amount of 80–100 µg was incubated with 4 nM [3H]-DAMGO (50 Ci/mmol) and FF3 dissolved in 50 mM 
assay buffer at pH 6.5 or 7.4 for 90 min at room temperature. Nonspecific binding was determined by the addi-
tion of 10 µM NLX20. Filters were soaked in 0.1% polyethyleneimine solution before use. Bound and free ligands 
were separated by rapid filtration under vacuum through Whatman GF/B glass fiber filters. Bound radioactivity 
was determined by liquid scintillation spectrophotometry at 69% counting efficiency for [3H] after overnight 
extraction of the filters in scintillation fluid. For [35S]-GTPγS-binding experiments, membranes were prepared 
as described above. After determination of protein concentration, membranes were centrifuged as described 
above and resuspended in [35S]-GTPγS-binding assay buffer (100 mM NaCl, 50 mM Tris Base, 5 mM MgCl2, 
Figure 5. Systemic FF3 induces central and intestinal side effects at high doses. (A) Effects of subcutaneous 
(s.c.) fentanyl, morphine, and FF3 presented as the area under the curve (AUC) of the distance (in cm) 
travelled during 30 min after drug injection (*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, Kruskal-Wallis 
one-way ANOVA and Dunn’s multiple comparison test; vehicle, fentanyl and FF3: n = 12, morphine: n = 10, 
means ± SEM). (B) Effects of s.c. fentanyl, morphine, and FF3 presented as the AUC of the time (s) spent on 
accelerating Rota-Rod at 2, 30 and 60 min after drug injection (**P < 0.01, ***P < 0.001 vs. vehicle, one-way 
ANOVA and Bonferroni’s multiple comparison test, n = 10). (C) Number of defecations in 1 h after s.c. fentanyl, 
morphine, and FF3 injection (*P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle, Kruskal-Wallis one-way ANOVA 
and Dunn’s multiple comparison test; vehicle, fentanyl and FF3: n = 12; morphine: n = 10, means ± SEM). (D) 
Effects of fentanyl, morphine, and FF3 on conditional place preference (*P < 0.05, **P < 0.01, ***P < 0.001 
vs. vehicle, one-way ANOVA and Bonferroni’ multiple comparison test; vehicle, fentanyl and FF3: n = 12, 
morphine: n = 10, means ± SEM).
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Figure 6. Effects of systemic FF3 on respiration and heart rate. Effects of subcutaneous (s.c.) morphine and 
FF3 at 5–60 min after injection compared to vehicle on heart rate (beats per min, bpm) (A), oxygen saturation 
(%) (B) and respiratory rate (breaths per min, brpm) (C) (#P < 0.05, ##P < 0.001, ###P < 0.001 vs. vehicle, 
two-way RM ANOVA and Bonferroni’s multiple comparison test; vehicle: n = 8; morphine and FF3: n = 10, 
means ± SEM).



















Table 2. Experimentally determined pKa values of clinically relevant opioid ligands. *No experimental values 
available, calculated values are stated.
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0.1 mM EGTA, 0.2% bovine serum albumin, 10 mM dithiotreitol and 0.03 mM GDP) adjusted to pH 7.4 or 6.522. 
A protein amount of 50 μg was incubated with 0.05 nM [35S]-GTPγS and varying concentrations of fentanyl or 
FF3 at the respective pH for 2 h at 30 °C to determine dose response curves and EC50 values. Whatman GF/B glass 
fiber filters were soaked in water before use. Bound and free [35S]-GTPγS was separated via rapid filtration as 
described above but for [35S]. Nonspecific binding was determined by the addition of 10 μM cold GTPγS. Basal 
[35S]-GTPγS-binding was measured in the absence of opioid ligand and cold GTPγS.
Transfection for FRET measurements. Culture and transfection of wild type HEK293 cells were per-
formed as previously described5. Briefly, cells were grown for 24 h (70–90% confluence) on 24 mm diameter glass 
coverslips coated with poly-L-lysine before transfection. 0.3–1 μg cDNA per construct were transfected with 
X-treme GENE HP DNA reagent (Sigma-Aldrich, Taufkirchen, Germany) following the supplier’s recommenda-
tions. The plasmid containing the cDNA encoding the FLAG-epitope-tagged rat MOR (oprm1, NM_013071.2) 
in pcDNA™3.1 vector was provided by Prof. C. Zöllner (University Hamburg, Germany). Rat Gαi1 (Gnai1, 
NM_013145.1) was tagged within the αb-αc loop (between residues 121 and 122) with a truncated enhanced 
cyan fluorescent monomeric Turquoise (mTqΔ6), to force the fluorophore into a FRET-promoting orientation23. 
Gαi1-mTqΔ6 and tetracysteine (TC)-tagged-Gβ1 (Gnb1, NM_030987.2) were subcloned into pcDNA™3.1 
expression vector between BamH1 or EcoRI and XhoI, respectively. A human construct with circular permu-
tated (cp) Venus-Gγ2 was kindly provided by Dr. M. Adjobo-Hermans (Department of Biochemistry, Radboud 
Institute for Molecular Life Science, The Netherlands). The rat variant of cpVenus-Gγ2 (Gng2, NM_001257349.1) 
and the PTX-resistant Gαi1-mTqΔ6 were generated by mutagenesis (N24S and C351I, respectively) using 
QuikChange™ Mutagenesis kit, and then checked by sequencing (Source Bioscience Sequencing, Berlin, 
Germany). The functionality of the transfected G-protein subunits was confirmed by preserved cAMP inhibition 
by fentanyl in the presence of PTX.
Real-time FRET measurements. At 48 h after transfection of HEK293 cells with MOR, Gβ1, Gαi1-mTqΔ6, 
and cpVenus-Gγ2, FRET between the latter two proteins was measured. Cells were briefly washed with PBS and 
subsequently equilibrated with assay buffer (140 mM NaCl, 5 mM KCl,2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 
10 mM Glucose) at different pH values. We used a FRET Nikon Eclipse TE2000-S widefield microscope equipped 
with a ultra-high-quality monochrome camera DS-Qi1, a Polychrome V monochromator and a DualView 
beam splitter to separate yellow fluorescent protein (YFP) (535 ± 15 nm) and cyan fluorescent protein (CFP) 
(480 ± 20 nm) emissions. Images of donor-donor (DD; excitation 439 nm/emission 480 nm), donor-acceptor 
(DA; excitation 439 nm/emission 535 nm) and acceptor-acceptor (AA; excitation 505 nm/emission 535 nm) were 
taken with a 40X objective (S fluor/1.30 oil) every 1 s with exposure times kept constant and comprised between 
50 (for Venus) and 150 ms (for mTq). Fluorescence intensities were quantified on regions of interest (ROI) includ-
ing the whole cell by NIS-Elements software. After background subtraction, NIS-Elements calculated FRET 
efficiency (in %), using the correction coefficients (CoA = 0.19; CoB = 0.43), accounting for bleed-through and 
direct YFP excitation from 3 independent experiments. On the day of the experiment, cells were washed and 
incubated with assay buffer (at pH 7.4 or 6.5) and after 20 s of live imaging, fentanyl, FF3 or vehicle (0.1% DMSO) 
were added at various concentrations for the remaining time. The experimenter was blinded to the treatment 
and buffer pH. ROIs with measured fluorescence intensities lower than 100 RFU in any of the recorded channels 
(DD, DA or AA) and with FRET % values lower than 1 were excluded prospectively. These exclusion criteria 
were established in preliminary experiments (showing unstable traces over time for ROIs corresponding to these 
exclusion criteria) and applied before unblinding. For each ROI, background-corrected fluorescence intensities 
(RFU ≥ 100) and corresponding FRET parameters (FRET efficiency ≥ 1%) over time were normalized to initial 
values (=1), pooled by experiment and finally averaged across the experiments. ΔFRET values for each treatment 
were derived by subtracting initial from final normalized FRET %. Finally, vehicle ΔFRET % was subtracted from 
each treatment in a pH-paired manner to yield net ΔFRET %.
Animals. Experiments were performed in male Wistar rats (200–300 g, Janvier, France) and were approved 
by the State animal care committee (Landesamt für Gesundheit und Soziales, Berlin). All experiments were 
performed in accordance with the relevant guidelines and regulations. The sample size was calculated with the 
G*Power 3.1.2 program (80% power and 0.05 level of significance). Animal experiments were stopped when 
specific termination criteria were reached (approved by the State animal care committee). The experimenter 
who performed experiments and analyzed the results was blinded to the interventions. Rats were kept on a 12 h 
dark-light cycle in groups of 3 in cages lined with ground corncob bedding with free access to food and water ad 
libitum and constant room temperature and humidity of 22 ± 0.5 °C and 60–65%, respectively. Before nociceptive 
testing, handling was performed once per day for 1–2 min. Animals were habituated to the test cages once or 
twice a day for 15 min, starting 4 days prior to the experiments. Statistical power calculations were performed to 
obtain the minimal number of animals for the experiments. After termination of the experiments, rats were killed 
by an overdose of isoflurane (AbbVie, Ludwigshafen, Germany).
Paw inflammation. Rats received an i.pl. injection of CFA (150 µl; Calbiochem, La Jolla, CA, USA) into the 
right hindpaw under brief isoflurane anesthesia24. Nociceptive testing was performed 4 days after CFA injection.
Paw incision. Unilateral hindpaw incision was induced under isoflurane anesthesia25. A 1 cm longitudinal 
incision through skin and fascia of the plantar aspect of the paw was made with a No. 11 blade. The starting point 
was 0.5 cm proximal of the heel’s edge and extending toward the toes. The plantaris muscle was lifted and incised 
longitudinally. The muscle origin and insertion remained intact. The wound was closed with silk sutures and 
experiments were performed 2 h after incision.
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Abdominal writhing. Animals received an i.p. injection of 10 ml/kg 1% acetic acid and were placed indi-
vidually into transparent cages for observation of abdominal constrictions (“writhing”)26. Writhes were recorded 
5–35 min thereafter.
Nerve injury. Chronic constriction injury (CCI) of the sciatic nerve was induced under isoflurane anesthe-
sia27. At the level of the left mid-thigh, 4 loose 4/0 silk ligatures were placed around the nerve and the wound was 
closed with silk sutures. Experiments were performed 14 days after CCI.
Injections and experimental protocols. Brief isoflurane anesthesia was applied for i.v. (200 μl), i.p., and 
injections at the site of the nerve injury (100 μl). Subcutaneous (s.c.) injections were performed without anesthe-
sia. Nociceptive tests were performed in separate groups of animals, before and 5–60 min after injections. NLXM 
was injected at the site of nerve injury immediately before i.v. injection of agonists. Pain thresholds were meas-
ured 15 min after injections. All dosages were determined in pilot experiments. The experimenter was blinded to 
the doses and drug treatments.
Mechanical hyperalgesia (Randall-Selitto test). Rats were gently held under paper wadding and incre-
mental pressure was applied via a wedge-shaped, blunt piston onto the dorsal surface of the hindpaws using an 
automated gauge (Ugo Basile, Comerio, Italy). The PPT necessary to induce paw withdrawal was determined by 
averaging three consecutive trials separated by 15 s intervals. The cut-off was set at 250 g to avoid tissue damage. 
The sequence of paws was alternated between animals to preclude order effects.
Mechanical allodynia (von Frey test). Rats were placed separately in clear Plexiglas cubicles located on a 
stand with anodized mesh. PWT was measured as described elsewhere28. Briefly, the plantar surface of the hind-
paw was stimulated with von Frey filaments with increasing force. PWT was reached if a filament produced with-
drawal responses to 3 stimuli. The strength of calibrated von Frey filaments was 0.6, 1, 1.4, 2, 4, 6, 8, 10, 15 and 26 g.
Heat hyperalgesia (Hargreaves test). Rats were placed separately in clear Plexiglas cubicles located on 
a stand with a glass surface. A high-intensity light bulb generated radiant heat was applied to the plantar surface 
of the hindpaws from underneath the glass surface. PWL was measured using an electronic timer as described29. 
Three measurements separated by at least 10 s were averaged. The heat intensity was adjusted to obtain a baseline 
withdrawal latency of about 10–12 s in uninjured paws, and the cut-off was 20 s.
Conditioned Place Preference (CPP). We used an unbiased counterbalanced CPP protocol in healthy rats 
as described previously5,30,31. The CPP boxes consist of light- and sound-attenuating chambers (60 × 30 × 30 cm; 
Ugo Basile) with two compartments separated by a removable door. The two compartments differed in wall color 
(black or white with black stripes) and floor texture (“grid” or “hole”). For habituation, each rat was placed into 
the chamber without separator to freely explore it for 30 min (days 1 and 2). In the pre-conditioning phase, each 
rat was placed into the unseparated chamber for 15 min and the time spent in each compartment was recorded 
(day 3). Rats showing high unconditioned preference for one of the two compartments were excluded from fur-
ther analysis, resulting in slightly differing animal numbers (n = 10–12). During conditioning, treatment and 
treatment-associated compartments were assigned randomly. Each rat underwent three 60 min conditioning ses-
sions receiving the test substance s.c. in one compartment (one session every other day), and three 60 min sessions 
receiving vehicle in the other compartment on the alternate days (days 4–9). On the test day (day 10), rats did not 
receive any drug and were allowed to freely explore the entire chamber (without separator) for 15 min. The time 
spent in each compartment was recorded using the AnyMaze software (Ugo Basile). Place preference was calcu-
lated as time spent in the drug-associated compartment subtracted by the time spent in the vehicle compartment.
Locomotor activity. Horizontal locomotor activity of healthy rats was measured in the CPP apparatus on 
the first day of conditioning of the CPP protocol (day 4). Locomotion was recorded by an infrared camera cou-
pled to a computer with AnyMaze software (Ugo Basile) and was measured as the distance (in cm) traveled in 
5 min intervals during 30 min after s.c. drug administration.
Motor coordination (Rota-Rod test). On the first day naïve rats were trained on the Rota-Rod (Ugo 
Basile) at 5 rotations per min (rpm). On days two and three the rotating speed was increased to 10 rpm until rats 
were able to stay on the Rota-Rod for 300 s (maximum 5 trials). On the testing day the data were recorded for 
three baseline trials prior to drug exposure, followed by three trials at 2, 30 and 60 min after s.c. drug injection 
at an accelerating speed (10–60 rpm over 300 s). The latency to fall was recorded for 3 successive attempts and 
averaged for each trial.
Respiratory depression and heart rate. We used a pulse oximeter (MouseOx, StarLife Sciences, 
Pittsburgh PA, USA) to measure heart rate, respiratory rate, and blood O2 saturation, as described previously5. 
Briefly, after 2 days of handling and 2 days of habituation (30 min/session), healthy rats were placed in a Plexiglass 
box wearing the pulse oximeter clip around the neck. The mean of two representative, error-free data sets, were 
calculated at each time point after s.c. injections.
Defecation. Excreta of individual rats were collected and counted for 1 h after s.c. drug administration on the 
first conditioning day in the CPP boxes.
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Data handling and statistical analyses. All data were assessed for normal distribution and equal vari-
ances by Kolmogorov-Smirnov test and/or D’Agostino test, and Pearson test. In dose-response experiments (dis-
placement binding and GTPγS-assay), means of values at each agonist concentration and each pH were calculated 
and used to derive IC50 and EC50 by nonlinear regression and were then subjected to unpaired t-test. In FRET 
experiments, dose-dependent responses were assessed by nonlinear regression setting as a constraint the maximal 
effect for each drug/pH condition. Normally distributed data were analyzed by one-way repeated measurements 
(RM)-ANOVA followed by Dunnett’s test.
Behavioral data were expressed as raw values or area under the curve. Two-sample comparisons were 
made using paired or unpaired t-test for normally distributed data, or Wilcoxon or Mann-Whitney test for 
non-normally distributed data. Changes over time (more than two time points) after one treatment were evalu-
ated using one-way RM-ANOVA followed by Bonferroni test for normally distributed data, or Friedman one-way 
RM-ANOVA followed by Dunn’s test for non-normally distributed data. Two-way RM-ANOVA and Bonferroni 
test were used to compare two parameters over time. Multiple comparisons at one time point were performed 
using one-way ANOVA followed by Dunnet’s test or Bonferroni’s multiple comparison test for normally distrib-
uted data, or by Kruskal-Wallis one-way ANOVA followed by Dunn’s test for non-normally distributed data. 
Differences were considered significant if P < 0.05. Prism 5 (GraphPad, San Diego, USA) was used for all tests and 
graphs and all data were expressed as means ± standard error of the mean (SEM).
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